|
|||||
|
|
Porcine recombinant factor VIII (Obizur; OBI‐1; BAX801): product characteristics and preclinical profile |
|
| Authors: | D. Lillicrap A. Schiviz C. Apostol P. Wojciechowski F. Horling C. K. Lai C. Piskernik W. Hoellriegl P. Lollar |
| Affiliation: | 1. Queen's University Kingston, Kingston, ON, Canada;2. Baxalta Innovations GmbH, Vienna, Austria;3. Baxalta US Inc., Milford, MA, USA;4. Emory University School of Medicine, Atlanta, GA, USA |
| Abstract: | |
| Keywords: | acquired haemophilia A bypass agents FVIII FVIII inhibitors Obizur recombinant porcine FVIII |